Therapeutic effect of creatine phosphate sodium combined alprostadil injection on acute-exacerbation CHF and its influence on serum NT-proBNP level / 心血管康复医学杂志

ABSTRACT

Objective: To explore therapeutic effect of creatine phosphate sodium (CP) injection combined alprostadil injection on acute-exacerbation chronic congestive heart failure (CHF) and its influence on serum level of N terminal pro B-type natriuretic peptide (NT-proBNP). Methods: A total of 120 acute-exacerbation CHF patients treated in our hospital were selected. According to random number table, they were randomly and equally divided into CP group (received CP injection based on routine treatment) and combined treatment group (received alprostadil injection based on CP group), and both groups were treated for two weeks. Cardiac output (CO), stroke volume (SV), left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDd) and serum NT-proBNP level before and after treatment, total effective rate and incidence rate of adverse reactions were measured and compared between two groups. Results: Compared with before treatment, after two-week treatment, there were significant rise in CO, SV and LVEF, and significant reduction in LVEDd in two groups except CO of CP group (P=0. 001 all); compared with CP group, after two-week treatment, there were significant rise in CO [(4. 9±1. 5) L vs. (5. 6±1. 6) L], SV [(70. 6±7. 5) ml vs. (79. 2±7. 6) ml]and LVEF [(42. 9±7. 6) ％ vs. (49. 3±8. 6) ％], and significant reduction in LVEDd [(58. 4±5. 3) mm vs. (43. 6±5. 5) mm]in combined treatment group, P＜0. 05 or＜0. 01. Compared with before treatment, there was significant reduction in serum NT-proBNP level in two groups on one and two weeks after treatment, and those of after two weeks were significantly lower than those of after one week, P=0. 001 all. Compared with CP group, after one-week and two-week treatment, there was significant reduction in serum NT-proBNP level [after one week (708. 6±137. 6) ng/L vs. (611. 4±121. 4) ng/L, after two weeks (573. 9±132. 9) ng/L vs. (359. 1±114. 2) ng/L]in combined treatment group, P=0. 001 all. Total effective rate of combined treatment group was significantly higher than that of CP group (95. 0％ vs. 81. 7％), P=0. 023. There was no significant difference in incidence rate of adverse reactions between two groups, P=0. 675. Conclusion: CP combined alprostadil can significantly improve cardiac function and total effective rate in acute-exacerbation CHF patients, which is worth extending.